Centessa Pharmaceuticals plc (CNTA)
- Previous Close
13.15 - Open
13.08 - Bid 9.24 x 200
- Ask 12.49 x 100
- Day's Range
12.22 - 13.08 - 52 Week Range
7.75 - 19.09 - Volume
488,049 - Avg. Volume
936,815 - Market Cap (intraday)
1.665B - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-2.06 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.11
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
centessa.comRecent News: CNTA
View More
Performance Overview: CNTA
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNTA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNTA
View MoreValuation Measures
Market Cap
1.66B
Enterprise Value
1.30B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.15
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.82%
Return on Equity (ttm)
-73.93%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-235.76M
Diluted EPS (ttm)
-2.06
Balance Sheet and Cash Flow
Total Cash (mrq)
482.18M
Total Debt/Equity (mrq)
29.34%
Levered Free Cash Flow (ttm)
-75.19M